Timber Pharmaceuticals, Inc. (TMBR) |
|
2.19 -0.09 (-3.95%)
|
02-07 16:00 |
|
Open: |
2.2363 |
Pre. Close: |
2.28 |
|
High:
|
2.3651 |
Low:
|
2.12 |
|
Volume:
|
84,291 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:32:15 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.1 One year: 3.62 |
| Support: |
Support1: 1.98  Support2: 1.56 |
| Resistance: |
Resistance1: 2.66 Resistance2: 3.1 |
| Pivot: |
2.2 |
| Moving Average: |
MA(5): 2.32 MA(20): 2.17
MA(100): 2.77 MA(250): 8.75 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 51 %D(3): 61.1 |
| RSI: |
RSI(14): 53.1 |
| 52-week: |
High: 20.54 Low: 0.24 |
| Average Vol(K): |
3-Month: 129 (K) 10-Days: 55 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TMBR ] has closed above bottom band by 47.3%. Bollinger Bands are 67.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.37 - 2.38 |
2.38 - 2.39 |
|
Low:
|
2.09 - 2.11 |
2.11 - 2.12 |
|
Close:
|
2.17 - 2.19 |
2.19 - 2.21 |
|
Company Description |
|
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey. |
Headline News |
Mon, 12 Dec 2022
Big downtown San Jose housing project could add hundreds of units - The Mercury News
Tue, 01 Nov 2022
TMBR: The Worst Biotech Stocks Investors Could Buy This Fall - StockNews.com
Tue, 25 Oct 2022
Is Timber Pharmaceuticals Inc (TMBR) Stock a Smart Investment Tuesday? - InvestorsObserver
Wed, 19 Oct 2022
MRVL: 4 Stocks That Have Taken a Turn for the Worse in 2022 - StockNews.com
Mon, 10 Oct 2022
VRTX: 2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell - StockNews.com
Mon, 03 Oct 2022
Why Timber Pharmaceuticals Shares Are Getting Hammered - Timber Pharmaceuticals (AMEX:TMBR) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
64 (M) |
|
% Held by Insiders
|
6.044e+007 (%) |
|
% Held by Institutions
|
5.2 (%) |
|
Shares Short
|
3,530 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
195.4 |
|
Return on Equity (ttm)
|
-67.1 |
|
Qtrly Rev. Growth
|
798910 |
|
Gross Profit (p.s.)
|
-0.26 |
|
Sales Per Share
|
0.02 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
74.94 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.69e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
